6-bromo-2,4-pteridinediamine | 16760-61-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 蝶啶及其衍生物
• 英文名称: 6-bromo-2,4-pteridinediamine
• 英文别名: 6-bromo-pteridine-2,4-diamine；6-bromopteridine-2,4-diamine
• CAS: 16760-61-5
• 化学式: C₆H₅BrN₆
• 分子量: 241.05
• InChiKey: JBCMGPUGHFLRJT-UHFFFAOYSA-N

物化性质

• 熔点：
  >300 °C
• 沸点：
  517.0±60.0 °C(Predicted)
• 密度：
  2.056±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  104
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  6-bromo-2,4-pteridinediamine 、 N-甲基-3,4,5-三甲氧基苯甲胺 反应 1.0h， 以31%的产率得到N~6~-Methyl-N~6~-[(3,4,5-trimethoxyphenyl)methyl]pteridine-2,4,6-triamine
  参考文献：
  名称：

  Folate antagonists. 18. Synthesis and antimalarial effects of N6-(arylmethyl)-N6-methyl-2,4,6-pteridinetriamines and related N6,N6-disubstituted 2,4,6-pteridinetriamines

  摘要：

  N6-(Arylmethyl)-N6-methyl-2,4,6-pteridinetriamines (1-15) and related N6-substituted 2,4,6-pteridinetriamines (16-20) were obtained by the condensation of 6-chloro-2,4-pteridinediamine with N-methylarylmethanamine and other selected secondary amines. The requisite N-methylarylmethanamines (21-32) were prepared by the hydrogenation over Pt/C of the corresponding arylcarboxaldehyde in the presence of methanamine. Several of the N6-(arylmethyl)-N6-methyl-2,4,6-pteridinetriamines exhibited exceptional suppressive antimalarial activity against a drug-sensitive line of Plasmodium berghei in mice. N6-Methyl-N6-(1-naphthalenylmethyl)-2,4,6-pteridinetriamine (9), the most active of these compounds, was also shown to be curative at 3.16 mg/kg in a single oral dose against P. cynomolgi in the rhesus monkey. This compound was also shown to be effective against a chloroquine-resistant line of P. berghei in the mouse but showed cross-resistance to a pyrimethamine-resistant strain. Most of the 2,4,6-pteridinetriamines showed strong antibacterial action against Streptococcus faecalis and Staphylococcus aureus.

  DOI：

  10.1021/jm00134a003
• 作为产物：
  描述：

  盐酸胍 、 3-氨基-2-氰基-6-溴吡嗪 在 sodium methylate 作用下， 以 甲醇 为溶剂， 反应 1.5h， 以83%的产率得到6-bromo-2,4-pteridinediamine
  参考文献：
  名称：

  Kinase inhibitors and methods of use thereof

  摘要：

  提供了用于治疗与血管稳态受损相关的疾病的组合物和方法。发明方法和组合物可用于治疗多种疾病，包括中风、心肌梗死、癌症、缺血/再灌注损伤、类风湿关节炎等自身免疫疾病、眼部疾病如葡萄膜炎、视网膜病变或黄斑变性、黄斑水肿或其他玻璃体视网膜疾病、自身免疫疾病、血管渗漏综合征、水肿或涉及白细胞活化的疾病、移植排斥反应、呼吸道疾病如哮喘、成人或急性呼吸窘迫综合征（ARDS）、慢性阻塞性肺疾病等。

  公开号：

  US20070259876A1

文献信息

• US7691858B2
  申请人：——

  公开号：US7691858B2

  公开（公告）日：2010-04-06
• [EN] KINASE INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE KINASES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：TARGEGEN INC

  公开号：WO2007127366A2

  公开（公告）日：2007-11-08

  [EN] Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as uveitis, retinopathies or macular degeneration, macular edema or other vitreoretinal diseases, inflammatory diseases such as automimmune diseases, vascular leakage syndrome, edema, or diseases involving leukocyte activation, transplant rejection, respiratory diseases such as asthma, adult or acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease, and the like.
  [FR] La présente invention concerne des compositions et des procédés de traitement de troubles apparentés à une compromission de la vasculostase. Les procédés et les compositions de l'invention sont utiles pour le traitement de divers troubles comprenant par exemple l'accident vasculaire cérébral, l'infarctus du myocarde, le cancer, l'ischémie / la lésion de reperfusion, des maladies auto-immunes telles que la polyarthrite rhumatoïde, des maladies oculaires telles que l'uvéite, les rétinopathies ou la dégénérescence maculaire, l'oeème maculaire ou d'autres maladies vitréo-rétiniennes, des maladies inflammatoires telles que des maladies auto-immunes, le syndrome de fuite vasculaire, l'oeème ou des maladies impliquant une activation des leucocytes, le rejet de greffe, des maladies respiratoires telles que l'asthme, le syndrome de détresse respiratoire de l'adulte ou aigu (SDRA), la maladie pulmonaire obstructive chronique et similaires.
• Folate antagonists. 18. Synthesis and antimalarial effects of N6-(arylmethyl)-N6-methyl-2,4,6-pteridinetriamines and related N6,N6-disubstituted 2,4,6-pteridinetriamines
  作者：Edward F. Elslager、Judith L. Johnson、Leslie M. Werbel

  DOI：10.1021/jm00134a003

  日期：1981.2

  N6-(Arylmethyl)-N6-methyl-2,4,6-pteridinetriamines (1-15) and related N6-substituted 2,4,6-pteridinetriamines (16-20) were obtained by the condensation of 6-chloro-2,4-pteridinediamine with N-methylarylmethanamine and other selected secondary amines. The requisite N-methylarylmethanamines (21-32) were prepared by the hydrogenation over Pt/C of the corresponding arylcarboxaldehyde in the presence of methanamine. Several of the N6-(arylmethyl)-N6-methyl-2,4,6-pteridinetriamines exhibited exceptional suppressive antimalarial activity against a drug-sensitive line of Plasmodium berghei in mice. N6-Methyl-N6-(1-naphthalenylmethyl)-2,4,6-pteridinetriamine (9), the most active of these compounds, was also shown to be curative at 3.16 mg/kg in a single oral dose against P. cynomolgi in the rhesus monkey. This compound was also shown to be effective against a chloroquine-resistant line of P. berghei in the mouse but showed cross-resistance to a pyrimethamine-resistant strain. Most of the 2,4,6-pteridinetriamines showed strong antibacterial action against Streptococcus faecalis and Staphylococcus aureus.
• Kinase inhibitors and methods of use thereof
  申请人：Doukas John

  公开号：US20070259876A1

  公开（公告）日：2007-11-08

  Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as uveitis, retinopathies or macular degeneration, macular edema or other vitreoretinal diseases, inflammatory diseases such as autoimmune diseases, vascular leakage syndrome, edema, or diseases involving leukocyte activation, transplant rejection, respiratory diseases such as asthma, adult or acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease, and the like.

  提供了用于治疗与血管稳态受损相关的疾病的组合物和方法。发明方法和组合物可用于治疗多种疾病，包括中风、心肌梗死、癌症、缺血/再灌注损伤、类风湿关节炎等自身免疫疾病、眼部疾病如葡萄膜炎、视网膜病变或黄斑变性、黄斑水肿或其他玻璃体视网膜疾病、自身免疫疾病、血管渗漏综合征、水肿或涉及白细胞活化的疾病、移植排斥反应、呼吸道疾病如哮喘、成人或急性呼吸窘迫综合征（ARDS）、慢性阻塞性肺疾病等。